US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GSK plc ADRhedged

71.56

-0.7881-1.09%

Post-market: 71.30-0.2619-0.37%16:10 EDT

Volume:212

Turnover:15.12K

Market Cap:715.69K

PE:- -

High:71.56

Open:71.36

Low:71.30

Close:72.35

52wk High:85.03

52wk Low:55.03

Shares:10.00K

Float Shares:10.00K

Volume Ratio:0.50

T/O Rate:2.12%

Dividend:2.08

Dividend Rate:2.90%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

GSK Advances New Toddler Pneumococcal Booster, Signaling Ongoing Vaccine Pipeline Momentum

GSK Supply Chain President Registers Sale of Ordinary Shares

GSK's ViiV Healthcare Highlights New Long-Acting Injectable Data on Cabenuva in HIV Treatment

MT Newswires Live

Cabenuva demonstrates superiority to daily oral therapy in adolescents with HIV

GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals

Benzinga Earnings

GSK Licensor's Late-Stage China Study for Risvutatug Rezetecan in Bone Cancer Meets Primary Endpoint

MT Newswires Live

GSK Heading in Right Direction, but Investors Might Stay on Sidelines

GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline

GSK to Build New Global Research Center in Cambridge

MT Newswires Live

Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Tuesday

MT Newswires Live

GSK's R&D Plan Looks Smart

GSK's Savings Plan Can Offset Profitability Hit from HIV Patent Expiration

GSK sees 70p per share dividend for FY26

GSK initiates ‘Accelerate Growth’ program

Sweeping job cuts at GSK to fund £400m Cambridge campus

GSK’s partner posts positive osteosarcoma data for B7-H3 drug, bolstering oncology push

GlaxoSmithKline (GSK) Receives a Hold from Deutsche Bank

GSK’s ViiV Healthcare presents data from Phase IIIb VOGUE study

GSK Strategy Update in Focus

GSK Canada Wins Approval for Prefilled Shingrix Syringe

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/GSKH/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":71.5619,"timestamp":1787601600000,"preClose":72.35,"halted":0,"volume":212,"hourTrading":{"tag":"盘后","latestPrice":71.3,"preClose":71.5619,"latestTime":"16:10 EDT","volume":6,"amount":429.3714,"timestamp":1787602204676,"change":-0.2619,"changeRate":-0.00366,"amplitude":0},"delay":0,"changeRate":-0.01089288182446441,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"Closed","change":-0.7881,"latestTime":"08-24 16:00:00 EDT","open":71.36,"high":71.5619,"low":71.3,"amount":15118,"amplitude":0.00362,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":72.35,"nav":72.35762,"aum":723648.55762,"dividendRate":0.029015,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":71.3,"preClose":71.5619,"latestTime":"16:10 EDT","volume":6,"amount":429.3714,"timestamp":1787602204676,"change":-0.2619,"changeRate":-0.00366,"amplitude":0},"volumeRatio":0.503563,"impliedVol":0.1195,"impliedVolPercentile":0.19},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.503563,"shares":10001,"dividePrice":2.0764,"high":71.5619,"amplitude":0.00362,"preClose":72.35,"low":71.3,"week52Low":55.03,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":71.5619,"eps":0,"divideRate":0.029015,"volume":212,"delay":0,"ttmEps":0,"open":71.36,"prevYearClose":68.2031,"prevWeekClose":72.35,"prevMonthClose":71.6488,"prevQuarterClose":73.8574,"fiveDayClose":69.8844,"twentyDayClose":72.7499,"sixtyDayClose":72.3943},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655804705","title":"GSK Advances New Toddler Pneumococcal Booster, Signaling Ongoing Vaccine Pipeline Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2655804705","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655804705?lang=en_us&edition=fundamental","pubTime":"2026-07-31 00:32","pubTimestamp":1785429167,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is running a Phase 1 trial called “A Phase 1, Observer-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-advances-new-toddler-pneumococcal-booster-signaling-ongoing-vaccine-pipeline-momentum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-advances-new-toddler-pneumococcal-booster-signaling-ongoing-vaccine-pipeline-momentum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4532","BK4588","GSK","LU1829250122.USD","GSKH","BK4585","GSK.UK","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655066588","title":"GSK Supply Chain President Registers Sale of Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2655066588","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655066588?lang=en_us&edition=fundamental","pubTime":"2026-07-30 22:32","pubTimestamp":1785421948,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) has provided an update. GSK disclosed that Regis Simard, the company’s President of Global Supply Chain, has sold 38,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-supply-chain-president-registers-sale-of-ordinary-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-supply-chain-president-registers-sale-of-ordinary-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","BK4007","LU1829250122.USD","GSKH","BK4585","BK4588","BK4532","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655894955","title":"GSK's ViiV Healthcare Highlights New Long-Acting Injectable Data on Cabenuva in HIV Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2655894955","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655894955?lang=en_us&edition=fundamental","pubTime":"2026-07-29 23:27","pubTimestamp":1785338827,"startTime":"0","endTime":"0","summary":"GSK's  majority-owned ViiV Healthcare unit reported trial data that back Cabenuva's, also known as cabotegravir plus rilpivirine, potential as a long-acting injectable HIV treatment, according to a Wednesday statement.The LATA trial's week 96 results demonstrated Cabenuva's superiority over daily oral therapy in 476 virologically suppressed adolescents of ages 12 to 19 years with HIV in certain African countries, GSK said. Meanwhile, data from the US-based OPERA cohort showed that Cabenuva maintained virologic suppression comparable with daily oral therapy in 6,800 adults with HIV, GSK added.GSK also said six-month follow-up data from the phase 1 CLARITY trial supported a \"more favorable\" injection experience with long-acting cabotegravir, compared with lenacapavir, after a single dose.The company is also investigating an intramuscular formulation of cabotegravir dosed three times a year for HIV prevention, with data to be presented at a future medical event, according to the statement","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4581","BK4532","LU1829250122.USD","BK4588","GSKH","XLV","XBI","LU0128526141.USD","HCSG","GSK.UK","BK4585","GSK","LU0029874061.USD","BK4137","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655997158","title":"Cabenuva demonstrates superiority to daily oral therapy in adolescents with HIV","url":"https://stock-news.laohu8.com/highlight/detail?id=2655997158","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655997158?lang=en_us&edition=fundamental","pubTime":"2026-07-29 22:25","pubTimestamp":1785335147,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK with Shionogi as a shareholder, announced data to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cabenuva-demonstrates-superiority-to-daily-oral-therapy-in-adolescents-with-hiv-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cabenuva-demonstrates-superiority-to-daily-oral-therapy-in-adolescents-with-hiv-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","BK4581","BK4007","LU1829250122.USD","XLV","GSK","BK4585","LABU","BK4532","GSKH","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655816808","title":"GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals","url":"https://stock-news.laohu8.com/highlight/detail?id=2655816808","media":"Benzinga Earnings","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655816808?lang=en_us&edition=fundamental","pubTime":"2026-07-29 01:30","pubTimestamp":1785259857,"startTime":"0","endTime":"0","summary":"GSK beats Q2 revenue and earnings estimates, launches a $2.52B cost-savings program, and updates its 2026 guidance.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/07/60737296/gsk-races-to-protect-profits-before-its-hiv-blockbuster-faces-generic-rivals","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","BK4585","BK4532","BK4007","GSK","BK4588","GSKH","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655888693","title":"GSK Licensor's Late-Stage China Study for Risvutatug Rezetecan in Bone Cancer Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2655888693","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655888693?lang=en_us&edition=fundamental","pubTime":"2026-07-28 23:54","pubTimestamp":1785254093,"startTime":"0","endTime":"0","summary":"GSK  licensor Hansoh's phase 3 trial of risvutatug rezetecan in osteosarcoma, the most common primary bone cancer, achieved its primary endpoint in progression-free survival, GSK said Tuesday.The trial, which was conducted in China in patients with osteosarcoma who have progressed or relapsed after receiving at least two prior lines of systemic therapy, showed that the therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy, according to the statement.Hansoh also reported consistent benefit across secondary endpoints like overall survival, GSK added.Safety profile was consistent with previous findings in the same tumor type, with no new safety signals identified, the company said. Hansoh will use the trial data for regulatory submissions in China, GSK said.Price: 53.96, Change: +1.98, Percent Change: +3.80","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GSKH","GSK.UK","LU1829250122.USD","GSK","BK4585","BK4532","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654886478","title":"GSK Heading in Right Direction, but Investors Might Stay on Sidelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2654886478","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654886478?lang=en_us&edition=fundamental","pubTime":"2026-07-28 22:10","pubTimestamp":1785247800,"startTime":"0","endTime":"0","summary":"1410 GMT - GSK's research-and-development plan seems a step in the right direction, but investors might stay on the sidelines until the U.K. drugmaker is closer to its destination, Citi analysts say in a research note. The company unveiled plans to target annual cost savings of 1.9 billion pounds by 2029 to fund its drug pipeline and aid profitability. The plan involves a new R&D center in Cambridge, England, and a faster development path for seven drugs across 18 indications, doubling the number of late-stage studies due to start this year, Citi says. \"Overall the ambition is heading in the right direction but we think the market will wait for delivery,\" the analysts say. Shares jump 6%.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","LU1829250122.USD","GSK.UK","GSKH","BK4007","ISBC","BK4211","GSK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654000299","title":"GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2654000299","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654000299?lang=en_us&edition=fundamental","pubTime":"2026-07-28 21:55","pubTimestamp":1785246900,"startTime":"0","endTime":"0","summary":"GSK said it is launching a three-year program to cut costs and reinvest in its drug pipeline, seeking to protect profitability from the patent expiration of a key HIV drug later this decade.The U.K. d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAQC","BK4588","LU1829250122.USD","GSK","BK4532","GSKH","BK4007","GSK.UK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654007170","title":"GSK to Build New Global Research Center in Cambridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2654007170","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654007170?lang=en_us&edition=fundamental","pubTime":"2026-07-28 21:16","pubTimestamp":1785244607,"startTime":"0","endTime":"0","summary":"GSK  said Tuesday it plans to establish a new global research and development facility within Cambridge Biomedical Campus in the UK and spend 400 million British pounds  over three years to construct the center and upgrade existing laboratories in Ware.The company said it will move its R&D operations in the UK to the new facility, which is expected to house over 1,000 researchers, and exit its current site in Stevenage through a gradual employee relocation ending by 2029.Shares of the company were up 2.1% in Tuesday premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4588","GSK","GSK.UK","BGSX","BK4585","BK4532","GSKH","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654007174","title":"Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2654007174","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654007174?lang=en_us&edition=fundamental","pubTime":"2026-07-28 21:15","pubTimestamp":1785244555,"startTime":"0","endTime":"0","summary":"Healthcare stocks were flat to higher pre-bell Tuesday, with the iShares Biotechnology ETF  inactive and the State Street Health Care Select Sector SPDR ETF  up 1.2%.GSK  shares were up more than 2% after the company posted higher Q2 core earnings and sales.IQVIA  stock was up more than 11% after the company reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.Centene  shares were down more than 5% even after the company reported that it swung to Q2 adjusted earnings as revenue increased during the period. Centene also lifted its 2026 guidance.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IQV","RGLO","LU0128526141.USD","BK4530","GSK.UK","VGFPF","JOYT","LU0980610538.SGD","LU2065171311.SGD","HEAL","DECU","LU0130518102.USD","LU0130517989.USD","LU1791710400.SGD","LU0130103400.USD","LU0648001328.SGD","LU2357627491.SGD","LU0029874061.USD","VOTE","FEBU","LU1201861165.SGD","BK4588","GSKH","CNCG","BK4585","LU0882574055.USD","XBI","GSK","LU0477156953.USD","LU1201861249.SGD","LU2065169927.USD","LU2362540622.SGD","CNC","LU1791710582.SGD","LU2362541273.HKD","EKG","XLV","HCSG","LABU","GXDW","BK4137","LU0528227936.USD","IBB","LU1261432733.SGD","LU1829250122.USD","BK4581","BK4154","PMDE","LU1989771016.USD","LU0130102774.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654002374","title":"GSK's R&D Plan Looks Smart","url":"https://stock-news.laohu8.com/highlight/detail?id=2654002374","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654002374?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:42","pubTimestamp":1785242520,"startTime":"0","endTime":"0","summary":"1242 GMT - GSK's plan to open a new research-and-development center in Cambridge, England, looks like a smart move that bodes well for its future prospects, Bernstein analysts say in a research note. \"We view this as a sound investment as this site already houses a major [AstraZeneca] R&D hub and two world leading academic hospitals,\" the analysts say. \"We think this should increase GSK's R&D productivity long term due to greater collaborations with academia.\" The U.K. drugmaker also plans more than 20 late-stage clinical trials to start this year, and is launching a three-year program to cut costs and fund investment in its late-stage portfolio, Bernstein says. Shares rise 1.4%.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","LU1829250122.USD","GSK.UK","GSKH","BK4007","GSK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654041060","title":"GSK's Savings Plan Can Offset Profitability Hit from HIV Patent Expiration","url":"https://stock-news.laohu8.com/highlight/detail?id=2654041060","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654041060?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:19","pubTimestamp":1785241140,"startTime":"0","endTime":"0","summary":"1219 GMT - GSK's new cost-cutting plan means it is now possible for the U.K. drugmaker to offset the profitability hit from an HIV drug going off patent later this decade, Intron Health's Naresh Chouhan and Dominic Rose say in a note. The company aims to cut annual costs by 1.9 billion pounds by 2029, leading to a stable or improving operating margin coinciding with the patent-expiration period for HIV drug dolutegravir between 2028 and 2030. This suggests consensus estimates could go up by 50 to 100 basis points, Intron says. Still, the company's target of generating more than 40 billion pounds in 2031 sales looks out of reach, the analysts say. Shares trade 0.3% higher.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","GSK","GSK.UK","BK4585","BK4532","GSKH","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654500183","title":"GSK sees 70p per share dividend for FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2654500183","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654500183?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:41","pubTimestamp":1785238881,"startTime":"0","endTime":"0","summary":"07:36 EDT GSK (GSK) sees 70p per share dividend for FY26 Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-sees-70p-per-share-dividend-for-fy26-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-sees-70p-per-share-dividend-for-fy26-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSKH","GSK.UK","LU1829250122.USD","GSK","BK4585","BK4532","BK4588","VIG","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654000188","title":"GSK initiates ‘Accelerate Growth’ program","url":"https://stock-news.laohu8.com/highlight/detail?id=2654000188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654000188?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:40","pubTimestamp":1785238820,"startTime":"0","endTime":"0","summary":"The company said, “Following review, the company has identified asset accelerations – across 18 indications – for 7 late-stage products in Oncology...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-initiates-accelerate-growth-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-initiates-accelerate-growth-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAQC","LU1829250122.USD","BK4585","BK4532","BK4588","GSK.UK","GSK","BK4007","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654018880","title":"Sweeping job cuts at GSK to fund £400m Cambridge campus","url":"https://stock-news.laohu8.com/highlight/detail?id=2654018880","media":"cityam","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654018880?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:02","pubTimestamp":1785236535,"startTime":"0","endTime":"0","summary":"GSK was reducing headcount in its back office to fund the campus GSK is poised to slash its back office headcount to help fund a 400m mega-campus in Cambridge, in a move it hopes will bolster its drugs pipeline and stave off a looming patent cliff edge.In his first major strategy update as chief executive, Luke Miels unveiled plans for the new 300,000 square foot site that will become the new home for its research and development arm and host more than 1,000 GSK scientists.The group is expected to launch a sweeping round of layoffs to help fund the investment and support the firm’s operating margin.Miels hailed the move, which will see it vacate its Stevenage research and development (R&D) site for Cambridge by 2029, as a shot in the arm for the FTSE 100 giant, which has lagged behind London-listed rival Astrazeneca and US peers in recent years.","market":"nz","thumbnail":"https://www.cityam.com/wp-content/uploads/2026/07/GSK-Cambridge-image-2.jpg?w=824&h=463&crop=1","type":0,"news_type":0,"thumbnails":["https://www.cityam.com/wp-content/uploads/2026/07/GSK-Cambridge-image-2.jpg?w=824&h=463&crop=1"],"rights":{"source":"cityam_highlight","url":"https://www.cityam.com/sweeping-job-cuts-at-gsk-to-fund-400m-cambridge-campus/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.cityam.com/sweeping-job-cuts-at-gsk-to-fund-400m-cambridge-campus/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cityam_highlight","symbols":["BK4532","BK4588","GSKH","GSK","LU1829250122.USD","BK4007","GSK.UK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654400342","title":"GSK’s partner posts positive osteosarcoma data for B7-H3 drug, bolstering oncology push","url":"https://stock-news.laohu8.com/highlight/detail?id=2654400342","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654400342?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:12","pubTimestamp":1785233546,"startTime":"0","endTime":"0","summary":"The latest update is out from GlaxoSmithKline ( ($GB:GSK) ). GSK’s licensor Hansoh Pharma has reported that its phase III ARTEMIS-011 trial of risv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-partner-posts-positive-osteosarcoma-data-for-b7-h3-drug-bolstering-oncology-push?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-partner-posts-positive-osteosarcoma-data-for-b7-h3-drug-bolstering-oncology-push?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","BK4588","BK4532","BK4585","BK4007","LU1829250122.USD","GSKH","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654021060","title":"GlaxoSmithKline (GSK) Receives a Hold from Deutsche Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2654021060","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654021060?lang=en_us&edition=fundamental","pubTime":"2026-07-28 08:55","pubTimestamp":1785200119,"startTime":"0","endTime":"0","summary":"Deutsche Bank analyst Emmanuel Papadakis reiterated a Hold rating on GlaxoSmithKline yesterday and set a price target of p1,950.00. According to Ti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-receives-a-hold-from-deutsche-bank-blurbs-news-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-receives-a-hold-from-deutsche-bank-blurbs-news-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4118","GSK.UK","GSK","DB","BK4585","BK4532","BK4007","LU1829250122.USD","BK4588","BK4552","BK4566","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654447210","title":"GSK’s ViiV Healthcare presents data from Phase IIIb VOGUE study","url":"https://stock-news.laohu8.com/highlight/detail?id=2654447210","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654447210?lang=en_us&edition=fundamental","pubTime":"2026-07-28 01:05","pubTimestamp":1785171922,"startTime":"0","endTime":"0","summary":"ViiV Healthcare announced data to be presented this week at the 26th International AIDS Conference in Rio de Janeiro, Brazil, from the phase IIIb V...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsks-viiv-healthcare-presents-data-from-phase-iiib-vogue-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsks-viiv-healthcare-presents-data-from-phase-iiib-vogue-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","LABU","BK4532","BK4588","LU0029874061.USD","XLV","EWZS","BK4581","XBI","HCSG","GSK","BK4585","BK4007","LU1829250122.USD","LU0128526141.USD","GSKH","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654408043","title":"GSK Strategy Update in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2654408043","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654408043?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:42","pubTimestamp":1785159720,"startTime":"0","endTime":"0","summary":"GSK is scheduled to report results for the second quarter on Tuesday. Here is what you need to know.TURNOVER FORECAST: Analysts expect the U.K. drugmaker to generate turnover of 8.24 billion pounds ($","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","BK4532","GSKH","LU1829250122.USD","BK4585","BK4007","GSK.UK","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653308107","title":"GSK Canada Wins Approval for Prefilled Shingrix Syringe","url":"https://stock-news.laohu8.com/highlight/detail?id=2653308107","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653308107?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:56","pubTimestamp":1784894167,"startTime":"0","endTime":"0","summary":"GSK  said Friday that Health Canada approved a prefilled syringe presentation of its shingles vaccine, Shingrix, eliminating the need to reconstitute separate vials before administration.The company said the approval was based on data demonstrating technical comparability between the new prefilled syringe and the existing presentation.GSK said it expects the new format to become available in Canada in early 2027.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4532","BK4588","GSK","LU1829250122.USD","GSKH","BK4585","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}